The Journal of Rheumatology最新文献

{"title":"Efficacy of Anti-TNF-α Inhibitors for Refractory Leg Ulcers in Cutaneous Polyarteritis Nodosa: A Case Series.","authors":"Kimie Harama,Takao Sugiyama,Chisaki Ito,Toyohiko Sugimoto,Soichiro Kubota,Ryosuke Ito,Yoshiaki Kobayashi,Shunichiro Hanai,Daiki Nakagomi","doi":"10.3899/jrheum.2025-0140","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0140","url":null,"abstract":"OBJECTIVECutaneous polyarteritis nodosa (cPAN) is a rare necrotizing vasculitis that primarily affects small-to-medium-sized arteries in subcutaneous tissue. cPAN is often characterized by a chronic and relapsing disease that presents with skin ulcers, livedo, and painful erythema. In this study, we evaluated the efficacy of anti-TNF-α inhibitor treatment for cPAN-associated refractory leg ulcers.METHODSThis retrospective study was conducted between 2016 and 2023 at three medical institutions in Japan and targeted patients with cPAN presenting with refractory leg ulcers who were treated with anti-TNF-α inhibitors. The diagnosis of cPAN was histologically confirmed, and patients with secondary PAN were excluded. Data on the clinical background, treatments, ulcer status, and glucocorticoid dosages were collected, and the therapeutic efficacy of the treatment was evaluated.RESULTSTen patients were included, with a mean age of 51 years, and nine were female. All patients presented with recurrent leg ulcers. Anti-TNF-α inhibitors included adalimumab (five cases), etanercept (four cases), and infliximab (one case). Complete epithelialization of the leg ulcers was achieved in all patients, and the average glucocorticoid dose was successfully reduced from 20 mg/day to 3.5 mg/day. Additionally, five patients achieved a glucocorticoid-free status. No serious adverse events were observed in any of the patients.CONCLUSIONAnti-TNF-α inhibitors suggested therapeutic efficacy for cPAN-associated refractory leg ulcers and enabled ulcer epithelialization and significant glucocorticoid dose reduction. These findings support the utility of anti-TNF-α inhibitors in the management of refractory leg ulcers in cPAN, highlighting the need for further large-scale studies to validate the results.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caribbean Crossroads in Rheumatology: Strategies to Establish Our Regional Rheumatic Disease Burden With Lessons and Opportunities for the Global Community.","authors":"Keisha Davis-King,Cindy Flower","doi":"10.3899/jrheum.2024-1214","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1214","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interferon Response Gene Score in Juvenile Dermatomyositis.","authors":"Hanna Kim","doi":"10.3899/jrheum.2025-0395","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0395","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Genetic Analysis of a Female Patient With Adolescent-Onset Gout.","authors":"Xia Li,Meng Zhang,Tong Pan,Jinjing Tian","doi":"10.3899/jrheum.2024-1282","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1282","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"109 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences with Complementary and Integrative Health Among People with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Qualitative Study.","authors":"Sarah L Patterson,Denise Ruvalcaba,Arbella Issa,Krish Rai,Patricia Katz,Christopher J Koenig","doi":"10.3899/jrheum.2024-1218","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1218","url":null,"abstract":"OBJECTIVERheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic immune-mediated inflammatory diseases often complicated by persistent pain and fatigue despite cutting edge pharmacological treatments. Lifestyle medicine (LM) and complementary and integrative health (CIH) offer adjuvant therapies with potential to alleviate these symptoms, but little is known about patients' experiences with these modalities.METHODSThis qualitative study explored the use of LM and CIH among English- and Spanish-speaking patients with RA and SLE. We conducted five focus groups using an original semistructured interview guide to examine participants' experiences with, and barriers to using, LM and CIH. Group discussions were recorded, transcribed verbatim, translated, and analyzed in a multi-step iterative process to identify frequencies and thematic trends.RESULTSThirty-nine participants with RA or SLE discussed using LM and CIH modalities to manage their disease in 130 mentions. Diet was the most frequently discussed lifestyle modality with participants noting specific foods that exacerbated or alleviated symptoms. Traditional Chinese Medicine (TCM) and natural products were the most discussed CIH approaches, and participants expressed a strong interest in exploring additional complementary modalities to mitigate symptoms. The primary barriers to using LM and CIH were uncertainty regarding safe and effective practices and high out-of-pocket expenses.CONCLUSIONPatients with RA and SLE are highly interested in using LM and CIH to manage their conditions, but many are unsure which adjunctive treatment approaches are safe and effective. More research on LM and CIH modalities is needed to facilitate clear, evidence-based answers to these common patient questions.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Calcium Pyrophosphate Crystal Arthritis Induced by Small Molecule Inhibitors in Anticancer Targeted Therapy: A Report of 2 Cases.","authors":"Elia Touma,Amir Bieber,Shay Brikman","doi":"10.3899/jrheum.2025-0027","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0027","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinically Inactive Disease and Remission in Patients with Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post-Hoc Analysis of a Phase III Trial.","authors":"Alessandro Consolaro,Nicolino Ruperto,Daniel J Lovell,Olga Synoverska,Carlos Abud-Mendoza,Alberto Spindler,Yulia Vyzhga,Ekaterina Alexeeva,Jeffrey Chaitow,Peter Chiraseveenuprapund,Irina Lazariciu,Lori Stockert,Mary Jane Cadatal,Annette Diehl,Hermine I Brunner,","doi":"10.3899/jrheum.2024-0536","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0536","url":null,"abstract":"OBJECTIVETo evaluate rates of clinically inactive disease and remission in patients with juvenile idiopathic arthritis (JIA) receiving tofacitinib, using the 2021 Juvenile Arthritis Disease Activity Score (JADAS) thresholds and American College of Rheumatology (ACR) criteria.METHODSThis post hoc analysis included patients with active JIA (polyarticular course JIA, psoriatic arthritis, or enthesitis-related arthritis) enrolled in a phase III, randomized, withdrawal study of tofacitinib. In part 1 (weeks 0-18) patients received open-label tofacitinib. In part 2 (weeks 18-44) patients who achieved ACR improvement ≥30% were randomized to tofacitinib or placebo for 26 weeks/until JIA flare. Disease activity was assessed using the JADAS in 10 joints (JADAS10), based on C-reactive protein, with interpretation as per 2021 polyarthritis thresholds. JADAS10 remission was defined as ≥24 continuous weeks of JADAS10 clinically inactive disease (JADAS10-CID). ACR clinically inactive disease (ACR-CID) and ACR clinical remission were also assessed.RESULTSOf 225 patients with JIA in part 1, 173 (76.9%) were randomized in part 2 to continue tofacitinib or switch to placebo. Rates of JADAS10-CID and ACR-CID increased throughout part 1 to 30.5% and 15.8% (week 18), respectively. In part 2, these were sustained with tofacitinib (week 44: JADAS10-CID: 35.2%; ACR-CID: 25.0%) and decreased when patients switched to placebo (week 44: JADAS10-CID: 25.9%; ACR-CID: 15.3%). A small proportion of patients achieved JADAS10 remission at week 44 (tofacitinib: 14.8%; placebo: 7.1%).CONCLUSIONIn patients with JIA receiving tofacitinib, JADAS10-CID and ACR-CID rates improved rapidly and were sustained over time; a small proportion of patients achieved JADAS10 remission. Inactive disease is a feasible treatment target in patients receiving tofacitinib.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Type of Joint Involvement With Distinct Clinical Features and Outcomes in Patients With Acute Parvovirus B19-Related Arthritis.","authors":"Bernardo D'Onofrio,Elisa Gremese,Carlo Selmi","doi":"10.3899/jrheum.2024-1025","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1025","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arthritis Mutilans in Psoriatic Arthritis: The Consequences of Delayed Treatment.","authors":"Deepti Agarwal,Kavita Krishna","doi":"10.3899/jrheum.2025-0012","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0012","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting Magnetic Resonance Imaging Structural Lesions in the Sacroiliac Joints.","authors":"Denis Poddubnyy","doi":"10.3899/jrheum.2025-0274","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0274","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}